Vicapsys Life Sciences (Vicapsys Life Sciences) Interest Expense : $-0.01 Mil (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vicapsys Life Sciences's interest expense for the three months ended in Sep. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vicapsys Life Sciences's Operating Income for the three months ended in Sep. 2023 was $ -0.18 Mil. Vicapsys Life Sciences's Interest Expense for the three months ended in Sep. 2023 was $ -0.01 Mil. Vicapsys Life Sciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vicapsys Life Sciences Interest Expense Historical Data

The historical data trend for Vicapsys Life Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Interest Expense Chart

Vicapsys Life Sciences Annual Data

Trend

Dec08

Dec09

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.32

Vicapsys Life Sciences Quarterly Data
	Jun10	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-0.01

Vicapsys Life Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Vicapsys Life Sciences (OTCPK:VICP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vicapsys Life Sciences's Interest Expense for the three months ended in Sep. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-0.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

Vicapsys Life Sciences's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Vicapsys Life Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024

Website

https://www.vicapsys.com

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Executives

Moore Bobby M Jr	10 percent owner	4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen	10 percent owner	9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski	director	1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping	10 percent owner	2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees	director	C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser	director	641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier	director	1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon	director, 10 percent owner	8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus

ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer

By ACCESSWIRE ACCESSWIRE • 04-13-2022